Open AccessChinese medicine for coronavirus disease 2019 as complementary therapy
Author(s) -
Min Zhou,
Qijun Liang,
Qiulan Pei,
Fan Xu,
Wen Huang
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000021034
Subject(s) - medicine , medline , odds ratio , randomized controlled trial , data extraction , meta analysis , confidence interval , family medicine , publication bias , systematic review , alternative medicine , intensive care medicine , pathology , political science , law
Background: The aim of this systematic review and meta-analysis is to assess effectiveness and safety of Chinese medicine (CM) as complementary therapy in treating coronavirus disease 2019 (COVID-19). Methods: The following databases will be searched: PubMed, Cochrane, Embase, China National Knowledge Infrastructure, Chinese Science and Technology Periodical Database, and Wanfang database from October 1, 2019 to March 1, 2020. Randomized trials and quasi-randomized or prospective controlled clinical trials of CM that reported data on COVID-19 patients will be included. Study selection, data extraction, quality assessment, and assessment of risk bias will be performed by 2 reviewers independently. Odds ratios and correlative 95% confidence intervals will be calculated to present the association between the CM and CWM using Review Manager version 5.3 when there is sufficient available data. Results: The results will be disseminated through a peer-reviewed journal publication. Conclusion: This systematic review findings will summarize up-to-date evidence for that CM is more effective and safe as adjunctive treatment for patients with COVID-19. Ethics and dissemination: Ethics approval and patient consent are not required as this study is a systematic review based on published articles. PROSPERO registration number: CRD42020185382.